Buscar
CervoMed Inc
CRVOAñadir a la lista de seguimiento
3.690USD
+0.590+19.03%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
34.16MCap. mercado
PérdidaP/E TTM
Más Datos de CervoMed Inc Compañía
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Información de CervoMed Inc
Símbolo de cotizaciónCRVO
Nombre de la empresaCervoMed Inc
Fecha de salida a bolsaNov 09, 2016
Director ejecutivoAlam (John J)
Número de empleados15
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección20 Park Plaza, Suite 424
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02116
Teléfono16177444400
Sitio Webhttps://cervomed.com/
Símbolo de cotizaciónCRVO
Fecha de salida a bolsaNov 09, 2016
Director ejecutivoAlam (John J)
Ejecutivos de CervoMed Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Director
Director
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Mr. Frank E. Zavrl
Mr. Frank E. Zavrl
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de CervoMed Inc?
Los cinco principales accionistas de CervoMed Inc son: Dr. Joshua S. Boger, Ph.D.
¿Cuántas instituciones poseen acciones de CervoMed Inc (CRVO)?
A fecha de 2026Q1, 130 instituciones poseen acciones de CervoMed Inc, con un valor de mercado combinado de aproximadamente 1.35M, lo que representa el 14.61% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2926415.00.